OLIPASS CORPORATION Logo

OLIPASS CORPORATION

Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.

244460 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

OLIPASS CORPORATION is a biotechnology company focused on the research and development of RNA therapeutics. The company's core technology is its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. This platform utilizes a modified PNA with covalently attached cationic lipid groups, which significantly enhances cell permeability. OPNA is designed to induce exon skipping by specifically binding to target pre-mRNA within the cell nucleus. This mechanism enables the development of a pipeline of novel therapeutic drug candidates for various diseases. The company's vision is to become a leading global R&D company in the field of RNA therapeutics.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for OLIPASS CORPORATION and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 11.7 KB
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 11.3 KB
2025-09-15 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Korean 10.7 KB
2025-09-12 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 16.1 KB
2025-09-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 63.1 KB
2025-09-10 00:00
Delisting Announcement
기타시장안내 (상장폐지 관련 이의신청서 접수)
Korean 2.9 KB
2025-09-08 00:00
M&A Activity
기타경영사항(자율공시) (공개매각을 위한 주간사계약 체결의 건)
Korean 5.5 KB

Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan 4978
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan 4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan 9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom RGP
ROXX, Inc. Logo
HR tech platform connecting non-desk job seekers with full-time roles using AI and vetting tools.
Japan 241A
SAFTEC CO.,LTD. Logo
Rents and sells safety equipment for construction, from basic supplies to AI/IoT solutions.
Japan 7464
Saniona Logo
Develops ion channel medicines for rare neurological diseases and epilepsy.
Denmark SANION
SBI Leasing Services Co.,Ltd. Logo
Structures Japanese Operating Leases for aircraft & ships for corporate investors.
Japan 5834
Sensorion Logo
Developing gene therapies and small molecules to restore, treat, and prevent hearing loss.
France ALSEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.